ABSTRACT

BACKGROUND: Interpretation of cardiac uptake on 18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is often confounded by intense physiological FDG uptake and numerous benign conditions. The aim of the study was to describe the echocardiographic features in concordance with cardiac and pericardial 18F-FDG uptake on whole-body oncology PET/CT.

METHODS: We enrolled 43 consecutive patients (34 solid tumors, 8 lymphomas and 1 leukemia) who were newly diagnosed with non-cardiac malignancy showing incidental cardiac or pericardial 18F-FDG uptake on PET/CT and underwent transthoracic Doppler echocardiography (TTE) within 1 month of PET/CT. The maximum standardized uptake (SUVmax) of all lesions was measured.

RESULTS: Fifty-six 18F-FDG uptake lesions (32 pericardium, 7 myocardium, 9 cardiac chambers and 8 great vessels) were found, and pericardial effusion was the most common echocardiographic finding (22/43, 51.2%) among study population. Pericardial FDG uptake was shown as pericardial effusion (68.8%), intrapericardial echogenic materials (31.3%), pericardial thickening (28.1%), hyperechogenicity of myopericardium (18.8%), and restricted sliding movement or constrictive pericarditis (15.6%) on TTE. Lesions with regional wall motion abnormality (p = 0.004) or constrictive pericarditis (p = 0.021) had significantly higher mean SUVmax of all lesions was measured.

RESULTS: Fifty-six 18F-FDG uptake lesions (32 pericardium, 7 myocardium, 9 cardiac chambers and 8 great vessels) were found, and pericardial effusion was the most common echocardiographic finding (22/43, 51.2%) among study population. Pericardial FDG uptake was shown as pericardial effusion (68.8%), intrapericardial echogenic materials (31.3%), pericardial thickening (28.1%), hyperechogenicity of myopericardium (18.8%), and restricted sliding movement or constrictive pericarditis (15.6%) on TTE. Lesions with regional wall motion abnormality (p = 0.004) or constrictive pericarditis (p = 0.021) had significantly higher mean SUVmax than those without. Myocardial FDG uptake demonstrated pericardial effusion (57.1%), regional wall motion abnormality (57.1%), and increased myocardial wall thickness (42.9%). All cardiac chamber FDG uptakes showed intracardiac mass on TTE.

CONCLUSIONS: Cardiac or pericardial 18F-FDG uptake on oncology PET/CT shows characteristic echocardiographic features according to which heart sites are involved.

Keywords: Cardiac metastases; 18F-FDG PET/CT; Echocardiography
INTRODUCTION

Cardiac metastases occur more frequently than primary cardiac tumors, with a highly variable incidence ranging from 2.3% to 18.3% in autopsy reports.\(^1\) Although in theory, any malignant tumor can metastasize to the heart, the most common tumors showing cardiac metastatic potential are lung cancer, breast cancer, hematologic malignancies and malignant melanoma.\(^2\)\(^-\)\(^5\) Whole-body oncologic positron emission tomography/computed tomography (PET/CT) using 2-\[^{18}\text{F}\]-fluoro-2-deoxy-D-glucose (FDG) is a useful imaging tool for cancer detection and staging that assesses tumor metabolic activity.\(^6\)\(^-\)\(^8\) However, cardiac uptake of \[^{18}\text{F}\]-FDG on PET/CT has been overlooked due to intense physiological myocardial FDG uptake and numerous benign conditions.\(^9\)\(^-\)\(^12\)

Transthoracic Doppler echocardiography (TTE) has been widely used as an initial imaging modality to provide information on hemodynamic consequences and the presence of cardiac metastases.\(^13\)\(^-\)\(^16\) To the best of our knowledge, there have been no studies comparing cardiac or pericardial \[^{18}\text{F}\]-FDG uptake on PET/CT with findings on TTE in patients with non-cardiac malignancy. The aim of this study is to investigate echocardiographic features corresponding to cardiac or pericardial \[^{18}\text{F}\]-FDG uptake on whole-body oncologic PET/CT.

METHODS

Study population

Forty-three consecutive patients (32 men, 11 women; mean age, 62 ± 19 years) with newly diagnosed non-cardiac malignancy showing cardiac or pericardial \[^{18}\text{F}\]-FDG uptake on oncologic whole-body PET/CT who underwent TTE within 1 month of PET/CT were retrospectively reviewed. The present study was approved by the Institutional Review Board and conducted with ethical principles of the Declaration of Helsinki. Written informed consent was obtained from all patients before enrollment.

The primary tumors of all patients were histopathologically confirmed by analysis of surgically resected tumor or tumor biopsies. Patients with previous history of primary cardiac tumor or cardiac surgery, coronary artery disease, atrial fibrillation, significant valvular heart disease, chronic obstructive pulmonary disease, acute infection or sepsis and poor image quality were excluded.

\[^{18}\text{F}\]-FDG PET/CT scanning

All scans were obtained using an integrated PET/CT inline system, either Biograph Duo or Biograph TruePoint (Siemens Medical Solutions, Knoxville, TN, USA). All patients fasted for at least 6h before the PET/CT study. Approximately 1h before PET/CT, each patient received an injection of 370-555 MBq of \[^{18}\text{F}\]-FDG. No patients had blood glucose levels > 130 mg/dL before the injection. There were 6-8 bed positions, and acquisition time was 2-3 min per bed position. Non contrast-enhanced CT was performed from the base of the skull to the upper thighs for attenuation correction and diagnosis (130kVp, 80mA, and 5-mm slice thickness; 120kVp, 50mA, and 5-mm slice thickness). PET immediately followed over the same body region, and images were reconstructed using a standard ordered-subset expectation maximization (OSEM) algorithm. The axial spatial resolution was 6.5 or 4.5mm at the center of the field of view.
Image analysis
All PET/CT images were reviewed at a workstation with fusion software (Syngo; Siemens Medical Solutions, Knoxville, TN, USA) that provided multi-planar reformatted images and displayed PET images after attenuation correction, CT images, and PET/CT fusion image. CT images were used to identify the location and morphological features of the lesion, in addition to its relation to surrounding tissues. 18F-FDG uptake in cardiac and pericardial lesions was quantified by calculating the maximum standardized uptake values (SUV<sub>max</sub>), which were obtained by normalizing the tissue concentration of FDG activity and patient weight. All PET/CT scans were reviewed and interpreted by 2 board certified nuclear medicine physicians who were blinded to the clinical data and the applied imaging convention.

TTE
All ultrasound examinations were performed with a commercially available echocardiographic device (vivid 7 [GE Vingmed Ultrasound AS, Horten, Norway], with a 2.5-MHz phased array probe). Standard M-mode, two-dimensional (2D), and color Doppler measurements were obtained according to the American Society of Echocardiography (ASE) recommendations. Briefly, echocardiographic data included morphology, size, location and echogenicity of metastatic lesions. Pericardial thickness greater than 4mm was defined as pericardial thickening. Left ventricular (LV) wall thickness and chamber dimension were measured from 2D-guided M-mode echocardiography. Regional LV myocardial wall motion was visually estimated by examining LV myocardial wall thickness and was classified as normal (normal wall thickening and motion), hypokinesia (reduced wall thickening and motion), and akinesia (absence of wall thickening and motion). Respiratory variation of ≥ 25% in mitral inflow peak early (E) velocity with abnormal septal notching or abrupt diastolic flattening of the posterior wall was considered diagnostic of constrictive pericarditis. Pulmonary venous (PV) velocities were also recorded, and monophasic flow or flow velocities > 1.6 m/s were regarded as functionally significant obstructions. Right ventricular (RV) chamber dimension and wall thickness were measured from the apical four-chamber view and subcostal view, respectively. All echocardiographic examinations were performed by skilled sonographers and interpreted by experienced cardiologists who were blinded to clinical information of the study population.

Statistical analysis
Data were analyzed using SPSS 18 software (SPSS, Inc., Chicago, IL. USA). Continuous variables were presented as the mean ± standard deviation (SD), and categorical data were presented as frequency percentages. Group comparison of mean SUV<sub>max</sub> was performed by Mann-Whitney U test. A p value < 0.05 was considered statistically significant.

RESULTS
Among 43 patients with cardiac or pericardial 18F-FDG uptake on PET/CT, the most frequent site of primary tumor was lung (15/43, 34.9%), followed by lymph node (8/43, 18.6%), thyroid (4/43, 9.3%), breast (3/43, 7.0%), liver (3/43, 7.0%), stomach (2/43, 4.7%), pleura (2/43, 4.7%) and five other sites (chronic myeloid leukemia [CML], mediastinum, esophagus, ovary, and metastasis of unknown origin [MUO]). Of 15 patients with lung cancer, 10 patients (66.7%) had non-small cell lung carcinoma (five each cases of adenocarcinoma and squamous cell carcinoma) and five (33.3%) had small cell lung carcinoma. All patients with lymphoma had non-Hodgkin’s lymphoma (diffuse large B-cell lymphoma in six patients and T cell lymphoblastic lymphoma in two patients). Thyroid cancer was follicular carcinoma in three
patients and anaplastic carcinoma in one patient. All three cases of breast cancer were invasive ductal carcinoma. The stomach cancer was adenocarcinoma and the pleural tumor was mesothelioma (Table 1).

**FDG uptake in the heart**

Although primary tumors tended to have a higher mean SUV<sub>max</sub> than those of metastatic lesions in the heart, the difference was not statistically significant (Figure 1). Of 43 patients, 33 patients (75.0%) had only one metastatic FDG uptake, including the pericardium in 29 patients, myocardium in three patients, and cardiac chamber in one patient. Among the rest, there were seven cases (16.3%) with FDG uptake in two sites (cardiac chamber and great vessel in five patients, pericardium and myocardium in two patients) and three cases (6.9%) with FDG uptake in three sites (myocardium, cardiac chamber, and great vessels in two patients, and pericardium, cardiac chamber, and great vessel in one patient) (Table 2).

**Echocardiographic features of metastatic FDG uptake lesions**

Among study population, pericardial effusion was the most common echocardiographic finding (22/43, 51.2%) in concordance with 18F-FDG uptake on PET/CT. Table 3 shows

| Pathology                                      | Cases, n (%) |
|-----------------------------------------------|--------------|
| Lung cancer                                   | 15 (34.9)    |
| Non-small cell lung carcinoma                 | 10           |
| Adenocarcinoma                                | 5            |
| Squamous cell carcinoma                       | 5            |
| Small cell lung carcinoma                     | 5            |
| Lymphoma (non-Hodgkin’s lymphoma)             | 8 (18.6)     |
| Diffuse large B-cell lymphoma                 | 6            |
| T cell lymphoblastic lymphoma                 | 2            |
| Thyroid cancer                                | 4 (9.3)      |
| Follicular carcinoma                          | 3            |
| Anaplastic carcinoma                          | 1            |
| Breast cancer (invasive ductal carcinoma)     | 3 (7.0)      |
| Hepatocellular carcinoma                      | 3 (7.0)      |
| Stomach cancer (adenocarcinoma)               | 2 (4.7)      |
| Pleural mesothelioma                          | 2 (4.7)      |
| Others*                                       | 6 (13.9)     |

*Chronic myeloid leukemia, mediastinum, esophagus, bladder, ovary, metastasis of unknown origin.

---

**Figure 1.** Comparison of mean SUV<sub>max</sub> between primary tumor and metastatic cardiac FDG uptake. FDG: fluorodeoxyglucose, HCC: hepatocellular carcinoma, SUV<sub>max</sub>: maximum standardized uptake value.
echocardiographic features according to the site of FDG uptake. Examples of each site are shown in Figure 2.

Table 2. Location of cardiac or pericardial fluorodeoxyglucose uptake on 18F-fluorodeoxyglucose positron emission tomography-computed tomography

| Location                                    | Cases, n (%) |
|---------------------------------------------|--------------|
| 1 lesion                                    | 33 (75.0)    |
| Pericardium                                 | 29           |
| Myocardium                                  | 3            |
| Cardiac chamber                             | 1            |
| 2 or more lesions                           | 10 (23.3)    |
| Cardiac chamber + great vessel               | 5            |
| Pericardium + myocardium                    | 2            |
| Myocardium + cardiac chamber + great vessel | 2            |
| Pericardium + cardiac chamber + great vessel| 1            |

Table 3. Echocardiographic features according to the location of FDG uptake on 18F-FDG positron emission tomography-computed tomography

| Location of FDG uptake                      | Cases, n (%) |
|---------------------------------------------|--------------|
| Pericardial 18F-FDG uptake                  | (n = 32)     |
| Pericardial abnormalities                   | 25 (78.1)    |
| Pericardial effusion                        | 22           |
| Intrapерicardial mass or materials          | 10           |
| Pericardial thickening                      | 9            |
| Hyperechogenicity of the myopericardium     | 6            |
| Decreased sliding motion of the pericardium | 3            |
| Constrictive pericarditis                   | 2            |
| Myocardial abnormalities                    | 32 (23.3)    |
| Regional wall motion abnormality            | 4            |
| Increased myocardial wall thickness         | 2            |
| Myocardial 18F-FDG uptake                   | (n = 7)      |
| Pericardial abnormalities                   | 6 (85.7)     |
| Pericardial effusion                        | 4            |
| Hyperechogenicity of the myopericardium     | 2            |
| Others*                                     | 4            |
| Myocardial abnormalities                    | 5 (71.4)     |
| Regional wall motion abnormality            | 4            |
| Increased myocardial wall thickness         | 2            |
| Cardiac chamber 18F-FDG uptake              | (n = 9)      |
| Intracardiac abnormalities                  | 9 (100.0)    |
| Mass in cardiac chamber                     | 4            |
| Pericardial abnormalities                   | 5 (55.6)     |
| Pericardial effusion                        | 4            |
| Hyperechogenicity of the myopericardium     | 1            |
| Myocardial abnormalities                    | 4 (11.1)     |
| Regional wall motion abnormality            | 1            |
| Other†                                      | 7            |
| Great vessel 18F-FDG uptake                 | (n = 8)      |
| Disturbance of SVC, IVC or PV inflow        | 5 (62.5)     |
| Pericardial abnormalities                   | 4 (50.0)     |
| Pericardial effusion                        | 3            |
| Hyperechogenicity of the myopericardium     | 1            |
| Intracardiac abnormalities                  | 3 (37.5)     |
| Mass in cardiac chamber                     | 3            |
| Myocardial abnormalities                    | 1 (12.5)     |
| Regional wall motion abnormality            | 1            |

18F-FDG: 18F-fluorodeoxyglucose, IVC: inferior vena cava, PV: pulmonary vein, SVC: superior vena cava.
*Intrapерicardial mass or materials, pericardial thickening, decreased sliding motion of the pericardium, constrictive pericarditis. †Disturbance of SVC, IVC or PV inflow.
Of 32 patients with pericardial FDG uptake, 25 patients (78.1%) showed pericardial abnormalities including pericardial effusion (88.0%), intrapericardial mass or materials (40.0%), pericardial thickening (36.0%), hyperechogenicity of the myopericardium (24.0%), decreased sliding motion of the pericardium (12.0%), and constrictive pericarditis (8.0%). Despite only two cases showed pericardial and myocardial FDG uptakes simultaneously, 6 patients (18.8%) demonstrated myocardial abnormalities such as regional wall motion abnormality (RWMA) (66.7%) and increased myocardial wall thickness (33.3%). Of 29 cases with FDG uptake limited to the pericardium, 17 cases (58.6%) showed pericardial abnormalities on TTE and their mean SUV\textsubscript{max} was not significantly different from that of others with normal echocardiogram (n=7) (7.4 ± 4.7 vs. 6.4 ± 4.8, \(p=0.684\)) (data not shown). When comparing the mean SUV\textsubscript{max} of pericardial FDG uptake lesions according to the type of abnormal echocardiographic features, lesions with RWMA (14.3 ± 4.7 vs. 6.4 ± 4.0, \(p=0.004\)) or constrictive pericarditis (13.1 ± 3.4 vs. 6.6 ± 4.1, \(p=0.021\)) had significantly higher mean SUV\textsubscript{max} than those without. Furthermore, lesions showing pericardial thickening (8.4 ± 6.1 vs. 6.8 ± 4.1, \(p=0.433\)) or increased pericardial echogenicity (10.1 ± 5.9 vs. 6.7 ± 4.3, \(p=0.138\)) were more likely to have higher mean SUV\textsubscript{max}. However, the presence of pericardial effusion or intrapericardial materials was not associated with mean SUV\textsubscript{max} (Figure 3).

Of seven cases with myocardial \(^{18}\)F-FDG uptake, 6 patients (85.7%) revealed pericardial abnormalities such as pericardial effusion (66.7%), hyperechogenicity of the myopericardium (33.3%), and others (Intrapericardial mass or materials, pericardial thickening, decreased sliding motion of the pericardium, constrictive pericarditis in one patient each). Among 5 patients showing myocardial abnormalities on TTE (71.4%), RWMA in 4 cases (80.0%) and increased myocardial wall thickness in 3 cases (60.0%) were found.

All nine cases with cardiac chamber \(^{18}\)F-FDG uptake revealed a mass in the cardiac chambers including the RA (6/9, 66.7%), RV outflow tract (1/9, 11.1%), RV (1/9, 11.1%), and LA (2/9, 22.2%).
22.2%) on TTE. Eight cases with great vessel 18F-FDG uptake included disturbances of SVC, IVC, or PV inflow in 5 cases (62.5%), pericardial effusion in 3 cases (37.5%), and intracardiac mass in 3 cases (37.5%). FDG uptake confined to the great vessels was not found.

DISCUSSION

18F-FDG uptake reflects glucose metabolism, and its uptake on PET/CT has been widely used as an imaging biomarker for cancer detection in oncology. Knowledge of pathological cardiac and pericardial FDG uptake on whole body PET/CT may provide important diagnostic clues to rule out metastatic involvement of the heart in patients with cancer or cancer screening. Here, we demonstrated for the first time echocardiographic features in concordance with cardiac and pericardial FDG uptakes that are incidentally encountered on oncology PET/CT among patients with non-cardiac malignancy.

Prior studies reported that the differentiation of focal pericardial FDG uptake from paracardiac lymph node uptake by 18F-FDG PET image is difficult. In this study, all but two patients showed focal pericardial FDG uptake, and we could exclude paracardiac nodal disease through FDG PET/CT fusion image. Pericardium was the most common site of FDG uptake however, only 60% of them revealed abnormal echocardiographic features and their mean SUV$_{\text{max}}$ was similar with that of normal echocardiogram. Although normal FDG uptake in the heart was adequately suppressed by prolonged fasting, the possibility of physiologic uptake or inflammation could not be completely excluded in our study. This result shows the limitation of oncology PET/CT for detecting cardiac metastasis, and also suggests that interpretation of cardiac FDG uptake, particularly in pericardium, should be cautious. Furthermore, we found that pericardial FDG uptake showing RWMA and constrictive pericarditis on TTE were more likely to have higher mean SUV$_{\text{max}}$ compared to other echocardiographic features. These findings seem to be inconsistent with previous reports demonstrating reduced FDG uptake in lesions of RWMA on TTE. However, most studies have been conducted in patients with coronary artery disease for assessing myocardial viability using cardiac PET/CT protocol. Considering that FDG uptake is related to metabolism, increased FDG uptake showing RWMA on TTE may strongly suggest cardiac metastasis. Accordingly, it is thought that aforementioned abnormal echocardiographic features
reflecting hemodynamic impairment could provide important clinical clues for metastatic pericardial FDG uptake.

It is difficult to detect malignant myocardial FDG uptake on oncology PET/CT because physiologic variations in FDG uptake can obscure abnormal myocardial FDG uptake. However, we used a strict preparation fasting regimen and excluded common patterns of normal physiologic FDG activity in the myocardium. In the present study, echocardiographic abnormalities were identified in all seven patients with myocardial FDG uptake. Interestingly, patients with myocardial FDG uptake alone showed not only myocardial structural or functional abnormalities but also pericardial abnormalities. These findings suggest that myocardial FDG uptake on oncology PET/CT could be a pathologic finding showing abnormal pericardial or myocardial abnormalities on TTE.

Most cases of FDG uptake in cardiac chambers on oncology PET/CT accompanied by involvement of the great vessels including the SVC, IVC, or PV, and some of them (7/9, 77.8%) also exhibited venous inflow disturbance on TTE. Considering that metastatic masses were usually located in RA or LA, our results suggest intracavitary cardiac metastases through a transvenous route. Echocardiography may be helpful to understand hemodynamic condition of these patients. Intracavitary space-occupying growth of a secondary heart tumor is rare, and it has been mainly reported in cancers of the kidney, liver, lung and thyroid. Meanwhile, in our study, involvement of the cardiac chambers and/or great vessels was most frequently found in lymphoma. This seems to be related to the pathophysiology of lymphoma that can metastasize to the heart through hematogenous dissemination, along with relatively high proportion of lymphoma in our study population.

Our study has several limitations. First, this is a retrospective study with potential selection and information biases. Second, there was no comparison with other adjunctive imaging modalities such as CT or MRI. Finally, all cardiac and pericardial FDG uptake lesions were not confirmed by pathology. Risks related to myocardial biopsy limit their routine use in clinical practice, especially for cancer patients. Moreover, it is challenging to capture a small piece of affected cardiac tissue. Thus, clinical data was acquired and analyzed to rule out benign cardiac or pericardial lesions with increased FDG uptake on PET/CT.

In conclusion, echocardiographic abnormality for cardiac or pericardial 18F-FDG uptake on oncologic PET/CT is not uncommon, and its echocardiographic features differ according to which heart sites are involved. Echocardiography may provide incremental morphologic and hemodynamic information in combination with anatomic and metabolic data obtained by FDG PET/CT. Further longitudinal prospective studies with a larger sample size are needed to establish the optimal imaging approach for increased FDG uptake in the heart during cancer staging.

REFERENCES

1. Bussani R, De-Giorgio F, Abbate A, Silvestri F. Cardiac metastases. J Clin Pathol 2007;60:27-34.
2. Bisel HF, Wroblewski F, Ladue JS. Incidence and clinical manifestations of cardiac metastases. J Am Med Assoc 1953;153:712-5.
3. Lam KY, Dickens P, Chan AC. Tumors of the heart. A 20-year experience with a review of 12,485 consecutive autopsies. Arch Pathol Lab Med 1993;117:1027-31. 
PUBMED
4. Butany J, Leong SW, Carmichael K, Komeda M. A 30-year analysis of cardiac neoplasms at autopsy. Can J Cardiol 2005;21:675-80. 
PUBMED
5. McDonnell PJ, Mann RB, Bulkley BH. Involvement of the heart by malignant lymphoma: a clinicopathologic study. Cancer 1982;49:944-51. 
PUBMED | CROSSREF
6. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol 2006;24:3282-92. 
PUBMED | CROSSREF
7. Fischman AI. Positron emission tomography in the clinical evaluation of metastatic cancer. J Clin Oncol 1996;14:691-6. 
PUBMED | CROSSREF
8. Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008;49:480-508. 
PUBMED | CROSSREF
9. Ding HJ, Shiau YC, Wang JJ, Ho ST, Kao A. The influences of blood glucose and duration of fasting on myocardial glucose uptake of [18F]fluoro-2-deoxy-D-glucose. Nucl Med Commun 2002;23:961-5. 
PUBMED | CROSSREF
10. Kaneta T, Hakamatsu K, Takanami K, et al. Evaluation of the relationship between physiological FDG uptake in the heart and age, blood glucose level, fasting period, and hospitalization. Ann Nucl Med 2006;20:203-8. 
PUBMED | CROSSREF
11. Fukuchi K, Ohta H, Matsumura K, Ishida Y. Benign variations and incidental abnormalities of myocardial FDG uptake in the fasting state as encountered during routine oncology positron emission tomography studies. Br J Radiol 2007;80:3-11. 
PUBMED | CROSSREF
12. Maurer AH, Burshteyn M, Adler LP, Steiner RM. How to differentiate benign versus malignant cardiac and paracardiac 18F FDG uptake at oncologic PET/CT. Radiographics 2011;31:1287-305. 
PUBMED | CROSSREF
13. Johnson MH, Soulen RL. Echocardiography of cardiac metastases. AJR 1983;141:677-81. 
PUBMED | CROSSREF
14. Kutalek SP, Panidis IP, Kotler MN, Mintz GS, Carver J, Ross JJ. Metastatic tumors of the heart detected by two-dimensional echocardiography. Am Heart J 1985;109:343-9. 
PUBMED | CROSSREF
15. Tominaga K, Shinkai T, Eguchi K, et al. The value of two-dimensional echocardiography in detecting malignant tumors in the heart. Cancer 1986;58:1641-7. 
PUBMED | CROSSREF
16. Auger D, Pressacco J, Marcotte F, Tremblay A, Dore A, Ducharme A. Cardiac masses: an integrative approach using echocardiography and other imaging modalities. Heart 2011;97:1101-9. 
PUBMED | CROSSREF
17. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233-70. 
PUBMED | CROSSREF
18. Naghuef SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2016;17:1321-60. 
PUBMED | CROSSREF
19. Klein AL, Abbara S, Agler DA, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr 2013;26:965-1012.e15. 
PUBMED | CROSSREF
20. Lobert P, Brown RK, Dvorak RA, Corbett JR, Kazerooni EA, Wong KK. Spectrum of physiological and pathological cardiac and pericardial uptake of FDG in oncology PET-CT. Clin Radiol 2013;68:e59-71. 
PUBMED | CROSSREF
21. Sheikine Y, Di Carli MF. Integrated PET/CT in the assessment of etiology and viability in ischemic heart failure. *Curr Heart Fail Rep* 2008;5:136-42. PUBMED | CROSSREF

22. Kobylecka M, Maczewska J, Fronczewska-Wieniawska K, Mazurek T, Plazińska MT, Królicki L. Myocardial viability assessment in 18FDG PET/CT study (18FDG PET myocardial viability assessment). *Nucl Med Rev Cent East Eur* 2012;15:52-60. PUBMED | CROSSREF

23. Reynen K, Köckeritz U, Strasser RH. Metastases to the heart. *Ann Oncol* 2004;15:375-81. PUBMED | CROSSREF

24. MacGee W. Metastatic and invasive tumours involving the heart in a geriatric population: a necropsy study. *Virchows Arch A Pathol Anat Histopathol* 1991;419:183-9. PUBMED | CROSSREF